Analysts Set Expectations for Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Chardan Capital issued their FY2025 EPS estimates for shares of Prothena in a research report issued on Monday, March 24th. Chardan Capital analyst R. Li expects that the biotechnology company will post earnings of ($3.25) per share for the year. Chardan Capital currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

Several other brokerages have also issued reports on PRTA. Royal Bank of Canada dropped their price target on Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Friday, February 21st. Oppenheimer boosted their target price on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research note on Friday, February 7th. StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and issued a $48.00 price objective on shares of Prothena in a report on Friday, February 21st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Prothena has a consensus rating of "Moderate Buy" and an average target price of $55.00.

Prothena Trading Down 7.3 %

Prothena stock traded down $0.97 during mid-day trading on Thursday, reaching $12.18. The company had a trading volume of 170,348 shares, compared to its average volume of 489,509. The business has a fifty day simple moving average of $14.32 and a 200 day simple moving average of $15.53. The company has a market cap of $655.34 million, a P/E ratio of -5.30 and a beta of -0.02. Prothena has a fifty-two week low of $11.70 and a fifty-two week high of $26.36.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRTA. Wellington Management Group LLP boosted its stake in Prothena by 22.8% in the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock worth $71,063,000 after purchasing an additional 952,088 shares in the last quarter. Boxer Capital Management LLC acquired a new position in Prothena in the fourth quarter valued at approximately $9,556,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Prothena by 1,122.9% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock worth $8,812,000 after purchasing an additional 483,673 shares during the period. Federated Hermes Inc. grew its position in Prothena by 84.3% during the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after buying an additional 341,274 shares during the period. Finally, Finepoint Capital LP increased its stake in shares of Prothena by 51.6% in the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company's stock valued at $9,100,000 after purchasing an additional 223,600 shares in the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.